Sera Laboratories International
Sera Laboratories International Ltd (Seralab) is an independent UK company providing a fast, friendly and efficient service with a focus on quality and traceability.
Seralab is a leading supplier of control matrices and disease state material from both human and animal models. The company offers the most complete range of human and animal-based research Bioproducts in Europe. Sera Lab provides serum, plasma, whole blood, tissues, microsomes, S9 fractions and fluids from the human model and an extensive range of animal species.
Our product range also includes Cell Culture sera and reagents including FBS, Cell Specific media selected growth factors and a range of standardised reagents and tools for all areas of Stem Cell research.
The Seralab technical and managerial team have, over 20 years, established an unrivalled reputation of working closely with our customers to develop individual, tailor made solutions; often through the development of new products and techniques.
Our commitment to traditional values of quality product, competitive pricing and absolute customer care are assured through our adherence to the spirit and application of ISO9001 accreditation, which we achieved in 2010. We constantly strive for service excellence providing reliability, full traceability and extensive quality control through customer led evolution and innovation.
Ms Jenny MurrayManaging Director
Ms Rosie Davies
Founded in 1976, Simbec Research is one of Europe's premier niche contract research organisations specialising in increasingly complex early clinical studies for the international pharmaceutical and biopharmaceutical industries.
Simbec is one of Europe's foremost CROs with over 35 years' experience in clinical drug development specialising in healthy volunteer and patient volunteer studies (Phase I-IIa). Simbec is a part of the Altasciences Group which means that as well as having laboratories in South Wales, United Kingdom, it also has facilities in Quebec, Canada. Combined facilities offer over 300 beds and an extensive volunteer and patient database.
Simbec have GCP, GLP, GMP and CPA Accreditation. We also have Standard and Supplementary MHRA Accreditation, meaning that as an Investigator Centre we are able to carry out clinical trials with compounds at all levels of risk, including those that require review by an Expert Advisory Group (EAG).
Simbec Clinical Pharmacology Unit (CPU) has extensive experience in conducting and managing safety, tolerability and pharmacokinetic studies, New Chemical Entity (NCE), First into Man, Proof of Concept, radiolabelled, bioavailability and bioequivalence studies, single and multi dose and short and long term studies.
Mr Gareth Harry
Dr Basia Kondratowicz
Sygnature Discovery is a leading United Kingdom-based provider of integrated drug discovery services to the global pharmaceutical industry. Key areas of expertise include medicinal and synthetic chemistry, computational chemistry and bioscience. Sygnature´s team of more than 50 industry-experienced scientists add considerable value to our clients´ programmes by undertaking key elements of the drug discovery process, such as hit finding, hit-to-lead, lead optimisation and complete integrated drug discovery projects.
Services on offer at Sygnature include:
- Medicinal Chemistry
- Synthetic Chemistry
- Computational Chemistry
- Bioscience (in vitro biology and screening)
- Arrays and Libraries
- Process and Scale-up Chemistry
- ADME/Toxicology (via a strategic alliance with Cyprotex Discovery)
Dr Paul Clewlow
Dr Simon Hirst
Theryte is a drug discovery and development company that is committed to bringing revolutionary new cancer treatments to market.
Theryte's new approach targets the processes that normally stabilise the cancer cell, allowing the creation of novel, first-in-class anti-cancer drugs with a unique mechanism of action and efficacy against difficult-to-treat tumours.
Theryte aims to exploit its patented discoveries to: (i) develop the breakthrough technology to select pre-clinical candidates for partnering and licensing; (ii) advance a new family of anticancer targets for further drug development; and (iii) develop biomarkers to predict treatment response.